Free Trial

CytomX Therapeutics (CTMX) Competitors

CytomX Therapeutics logo
$2.25 -0.14 (-5.86%)
Closing price 04:00 PM Eastern
Extended Trading
$2.27 +0.02 (+0.93%)
As of 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CTMX vs. OCS, VIR, NAGE, ANAB, AVBP, MNMD, IOVA, AMLX, CRMD, and TNGX

Should you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include Oculis (OCS), Vir Biotechnology (VIR), Niagen Bioscience (NAGE), AnaptysBio (ANAB), ArriVent BioPharma (AVBP), Mind Medicine (MindMed) (MNMD), Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals (AMLX), CorMedix (CRMD), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry.

CytomX Therapeutics vs. Its Competitors

Oculis (NASDAQ:OCS) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

Oculis currently has a consensus target price of $35.33, suggesting a potential upside of 95.21%. CytomX Therapeutics has a consensus target price of $5.33, suggesting a potential upside of 137.04%. Given CytomX Therapeutics' higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Oculis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oculis
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
CytomX Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

22.3% of Oculis shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 6.6% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, CytomX Therapeutics had 1 more articles in the media than Oculis. MarketBeat recorded 2 mentions for CytomX Therapeutics and 1 mentions for Oculis. Oculis' average media sentiment score of 1.89 beat CytomX Therapeutics' score of 1.54 indicating that Oculis is being referred to more favorably in the media.

Company Overall Sentiment
Oculis Very Positive
CytomX Therapeutics Very Positive

CytomX Therapeutics has a net margin of 28.22% compared to Oculis' net margin of -13,788.70%. Oculis' return on equity of -92.95% beat CytomX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oculis-13,788.70% -92.95% -70.03%
CytomX Therapeutics 28.22%-553.71%32.21%

Oculis has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500.

CytomX Therapeutics has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oculis$780K1,013.14-$97.43M-$2.64-6.86
CytomX Therapeutics$138.10M1.31$31.87M$0.484.69

Summary

CytomX Therapeutics beats Oculis on 11 of the 14 factors compared between the two stocks.

Get CytomX Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CTMX vs. The Competition

MetricCytomX TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$192.68M$3.02B$5.70B$9.56B
Dividend YieldN/A2.40%4.71%4.06%
P/E Ratio4.6921.0028.1919.94
Price / Sales1.31331.94459.6596.38
Price / Cash6.6042.5736.3258.72
Price / Book-225.008.138.295.77
Net Income$31.87M-$55.06M$3.25B$259.21M
7 Day Performance-5.86%0.88%0.21%-0.80%
1 Month PerformanceN/A15.04%8.71%9.81%
1 Year Performance58.45%2.54%32.76%14.37%

CytomX Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CTMX
CytomX Therapeutics
4.1439 of 5 stars
$2.25
-5.9%
$5.33
+137.0%
+59.3%$192.68M$138.10M4.69170Positive News
High Trading Volume
OCS
Oculis
2.2236 of 5 stars
$17.50
flat
$35.33
+101.9%
+54.0%$764.09MN/A-6.632
VIR
Vir Biotechnology
3.4848 of 5 stars
$5.52
+2.0%
$30.25
+448.0%
-48.8%$763.09M$74.21M-1.31580
NAGE
Niagen Bioscience
1.4107 of 5 stars
$9.68
-4.7%
$13.22
+36.6%
N/A$762.49M$99.60M56.94120
ANAB
AnaptysBio
1.8299 of 5 stars
$26.17
+1.0%
$42.38
+61.9%
-28.3%$761.54M$91.28M0.00100News Coverage
Upcoming Earnings
AVBP
ArriVent BioPharma
2.1613 of 5 stars
$21.55
-2.3%
$39.29
+82.3%
-6.5%$754.39MN/A0.0040Positive News
MNMD
Mind Medicine (MindMed)
2.0012 of 5 stars
$9.95
+12.0%
$25.50
+156.3%
+3.0%$751.72MN/A-7.7140News Coverage
High Trading Volume
IOVA
Iovance Biotherapeutics
4.5315 of 5 stars
$2.49
+11.7%
$12.22
+390.9%
-68.1%$744.67M$164.07M0.00500High Trading Volume
AMLX
Amylyx Pharmaceuticals
3.38 of 5 stars
$8.21
-1.6%
$11.75
+43.1%
+305.6%$743.44M$87.37M0.00200Positive News
CRMD
CorMedix
2.7397 of 5 stars
$10.94
+0.7%
$17.14
+56.7%
+163.9%$736.58M$43.47M49.3630
TNGX
Tango Therapeutics
1.8673 of 5 stars
$6.77
flat
$10.50
+55.1%
-31.6%$733.80M$42.07M-5.5590News Coverage
Positive News
Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:CTMX) was last updated on 7/29/2025 by MarketBeat.com Staff
From Our Partners